Robert Forrester

Robert Forrester has a diverse work experience in the biopharmaceutical industry. Robert is currently a Director at OnCusp Therapeutics, where they contribute to the development and commercialization of oncology therapeutics. Prior to this role, they held positions as a Director at AffyImmune, IDRx, Deciduous Therapeutics, and EyeCool Therapeutics, where they gained experience in cancer immunotherapy, precision combination therapies for cancer care, and immunotherapies for clearing senescent cells.

In 2020, Forrester served as a Director at Pillar Biosciences Incorporated, a company specializing in next-generation sequencing (NGS) testing technology for cancer patients. Robert also co-founded and advised EQRx, a company dedicated to making innovative medicines more affordable and accessible.

Earlier in their career, Forrester was the President, Chief Executive Officer, and Director at Verastem Oncology, a biopharmaceutical company focused on developing cancer medicines. Robert also served as a Director at Gelesis, contributing to their work in the healthcare industry.

Overall, Forrester's work experience demonstrates their expertise in oncology therapeutics, immunotherapy, precision medicine, and drug development.

Robert Forrester attended the University of Bristol from 1981 to 1984, where they earned a Bachelor of Laws (LLB) degree. Robert then pursued further education at the University of Law Guildford, UK from 1984 to 1985. In 1989, they attended the London Business School and obtained a Certificate in Finance and Entrepreneurship (CFE).